Probiotic Reduces Infant Respiratory Infections by Thirty Percent
A probiotic called Bifidobacterium animalis subsp. lactis BB-12 (BB-12) reduced the rate of respiratory infections in newborn babies by 30%, according to research published in the British Journal of Nutrition last week.
A probiotic called Bifidobacterium animalis subsp. lactis BB-12 (BB-12) reduced the rate of respiratory infections in newborn babies by 30%, according to research published in the British Journal of Nutrition last week.
In the double-blind, placebo-controlled study, researchers in Finland and Denmark tested the effects of two daily doses of the probiotic (as a tablet) versus a control tablet in 109 healthy one-month old babies up until eight months of age. Breast-feeding durations and symptoms of respiratory infections were recorded.
At eight months, 95% of the control group experienced respiratory infections compared to 65% of the BB-12 group. No differences in breast-feeding duration were recorded across the two groups.
BB-12 is supplied by Chr. Hansen (Hørsholm, Denmark). For more information on the probiotic, visit Chr. Hansen here.
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.
